Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | SVP, Commercial Operations | May 17, 2021 | May 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date May 17, 2021 · Filed May 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,061 |
Reported balance
After 2021-05-17 transaction · row 1
1 source rowRow 1 · 2021-05-17 · Grant · Acquired 29,061 · Balance 29,061 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.41 · Expires 2031-05-17 | Direct | 72,653 |
Reported balance
After 2021-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-17 · Grant · Acquired 72,653 · Balance 72,653 F1: The options vest with respect to 1/4 of such shares on May 15, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest with respect to 1/4 of such shares on May 15, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2021 Filed May 19, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 72,653 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001209191-21-034233 · doc4.xml · derivative · entry 2 THORSEN HENNING · CIK 0001854505 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,653 Underlying: Common Stock · 72,653 shares Expires 2031-05-17 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on May 15, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 29,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034233 · doc4.xml · nonDerivative · entry 1 THORSEN HENNING · CIK 0001854505 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,061 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.